Should You Scoop Up Shares of This Promising Biotech on the Dip?

Should You Scoop Up Shares of This Promising Biotech on the Dip?
·4 min read

The group of technologies that enable gene editing help scientists modify an organism's DNA. Let's look at one of the more prominent pure-play gene-editing stocks on the market: Editas Medicine (NASDAQ: EDIT). This company recently took a nosedive following a disappointing clinical update.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting